(Z)-N-(azepan-1-yl)-3-[3-[3-methyl-5-(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]prop-2-enamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (Z)-N-(azepan-1-yl)-3-[3-[3-methyl-5-(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]prop-2-enamide
• 化学式: C₁₉H₂₂F₃N₅O
• 分子量: 393.4
• InChiKey: SKLBDJXGYBWESJ-TWGQIWQCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  63
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• Hydrazide Containing Nuclear Transport Modulators And Uses Thereof
  申请人：Karyopharm Therapeutics Inc.

  公开号：US20150274698A1

  公开（公告）日：2015-10-01

  The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I: or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

  本发明通常涉及核运输调节剂，例如CRM1抑制剂，更具体地涉及由结构式I表示的化合物：或其药学上可接受的盐，其中变量的值和可替换值如本文所定义和描述。本发明还包括合成和使用结构式I的化合物，或其药学上可接受的盐或组合物，例如在治疗、调节和/或预防与CRM1活性相关的生理状况中的应用。
• HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF
  申请人：Karyopharm Therapeutics, Inc.

  公开号：US20140235653A1

  公开（公告）日：2014-08-21

  The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I: or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

  本发明通常涉及核运输调节剂，例如CRM1抑制剂，更具体地涉及由结构式I表示的化合物或其药学上可接受的盐，其中变量和备选变量的值如本文所定义和描述的那样。本发明还包括合成和使用结构式I的化合物，或其药学上可接受的盐或组合物，例如在治疗、调节和/或预防与CRM1活性相关的生理状况中使用。
• Hydrazide containing nuclear transport modulators and uses thereof
  申请人：Karyopharm Therapeutics Inc.

  公开号：US10544108B2

  公开（公告）日：2020-01-28

  The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I: or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

  本发明一般涉及核转运调节剂，例如 CRM1 抑制剂，尤其是结构式 I 所代表的化合物： 或其药学上可接受的盐，其中变量的值和替代值如本文所定义和描述。本发明还包括结构式 I 的化合物或其药学上可接受的盐或组合物的合成和使用，例如用于治疗、调节和/或预防与 CRM1 活性相关的生理状况。
• Hydrazide Containing Nuclear Transport Modulators and Uses Thereof
  申请人：Karyopharm Therapeutics Inc.

  公开号：US20160304472A1

  公开（公告）日：2016-10-20

  The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I: or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.
• Methods of Promoting Wound Healing Using CRM1 Inhibitors
  申请人：KARYOPHARM THERAPEUTICS INC.

  公开号：US20160304500A1

  公开（公告）日：2016-10-20

  The invention generally relates to the use of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof, wherein Ring A, X, R 1 , R 2 and n are as defined and described herein, in a method for promoting wound healing in a subject.